The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy.
The prognosis for people with the high-grade brain tumor glioblastoma is very poor, due largely to low cell death in response to genotoxic therapy. The transcription factor BCL6, a protein that normally suppresses the DNA damage response during immune cell maturation, and a known driver of B-cell ly...
Main Authors: | Marie-Sophie Fabre, Nicole M Stanton, Tania L Slatter, Samuel Lee, Dinindu Senanayake, Rosemary M A Gordon, M Leticia Castro, Matthew R Rowe, Ahmad Taha, Janice A Royds, Noelyn Hung, Ari M Melnick, Melanie J McConnell |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0231470 |
Similar Items
-
Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6
by: Nina Kerres, et al.
Published: (2017-09-01) -
Alpha-enolase is upregulated on the cell surface and responds to plasminogen activation in mice expressing a ∆133p53α mimic.
by: Sonal Sawhney, et al.
Published: (2015-01-01) -
EPS8 is a Potential Oncogene in Glioblastoma
by: Yang G, et al.
Published: (2019-12-01) -
Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
by: Yiru Zhang, et al.
Published: (2018-05-01) -
Long Non-coding RNA ANRIL in the Nucleus Associates With Periostin Expression in Breast Cancer
by: Paulomi M. Mehta-Mujoo, et al.
Published: (2019-09-01)